Business Context and Reporting Period
This Form 8-K was filed by Graphite Bio, Inc. (trading symbol: GRPH) on July 28, 2023. The report discloses a corporate governance change involving the Board of Directors. Note: The request metadata referenced "LENZ Therapeutics, Inc.", but the filing text explicitly identifies the registrant as Graphite Bio, Inc.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on the appointment of a new director and does not contain financial performance data.
Material Changes
- Board Expansion: The Board of Directors increased its size from ten to eleven members.
- New Appointment: Kimberlee C. Drapkin was appointed as a director, effective immediately.
- Term: Ms. Drapkin will serve until the 2024 annual meeting of stockholders or until her successor is elected, qualified, or until earlier death, resignation, or removal.
- Independence: The Board determined Ms. Drapkin is independent under Nasdaq rules.
Management Commentary and Compensation
Ms. Drapkin brings over 25 years of experience in biotechnology and pharmaceutical finance, including roles as CFO at Jounce Therapeutics, Inc., EPIX Pharmaceuticals, Inc., and Millennium Pharmaceuticals, Inc. She currently serves on the boards of Acumen Pharmaceuticals, Imugene Limited, and Kineta, Inc.
- Compensation: She will receive cash and equity compensation per the Company's Director Compensation Policy, with cash prorated based on her appointment date.
- Agreements: She will enter into a standard indemnification agreement.
- Conflicts: No family relationships or undisclosed transactional interests exist between Ms. Drapkin and other directors or officers.
Investor Verification Checklist
- Verify the exact terms of the Director Compensation Policy referenced in the 2023 Proxy Statement.
- Confirm the independence status of the new director against current Nasdaq listing standards.
- Review the Company's upcoming 2024 annual meeting schedule for the election of the new director.
- Check for any subsequent filings regarding changes to the Board composition or executive leadership.